FluMist Home taps living rooms for flu defense

The FDA approved a self-administered nasal flu vaccine delivered to homes in 34 states, aiming to boost uptake this season.

FluMist Home expands vaccine access

AstraZeneca has made FluMist Home available for home delivery in 34 states. The nasal flu vaccine can be self-administered by adults under 50 and children as young as 2, after a brief online medical screening that is reviewed by a licensed clinician before prescribing. The vaccine arrives in temperature controlled packaging with two pre-measured nasal doses and a temperature tag to ensure it stayed within range during shipping. It is eligible for coverage by most commercial insurance plans, with an $8.99 shipping and handling fee. The FDA approved home self-administration in September 2024, but delivery to households was delayed until now. The vaccine uses the same live, weakened influenza virus as clinic versions and is the only needle free option for flu vaccination in the US. Common side effects include runny nose and congestion; fever can occur in young children and a sore throat in adults.

The move could reduce practical barriers to vaccination, such as scheduling and travel to clinics. If uptake rises, it may strengthen protection across communities during the peak season. At the same time, it raises questions about privacy, cold chain logistics, and whether all households will have equal access to online screening and prompt delivery. The broader shift toward home health products suggests care is increasingly designed around busy lives, but policymakers will watch for gaps in access and potential safety concerns for first time users.

Highlights

The flu season will test how quickly home based health options scale for everyday care.